JP2023106548A - Composition for suppressing increase in triglyceride in blood - Google Patents

Abstract

To provide a composition for suppressing an increase in triglyceride in blood, the composition having a dramatically improved effect of suppressing the increase in triglyceride in blood.SOLUTION: Provided is a composition for suppressing an increase in triglyceride. The composition comprises indigestible dextrin as an active ingredient. The composition further comprises one or more amino acids selected from alanine and valine.SELECTED DRAWING: Figure 3

Description

TECHNICAL FIELD The present invention relates to a composition for suppressing elevation of blood neutral fat, and more particularly to a composition for suppressing elevation of blood neutral fat containing indigestible dextrin and specific other ingredients as active ingredients.

Indigestible dextrin is known to have various functions to regulate the condition of the body, one of which is known to be an inhibitory effect on the elevation of triglycerides in the blood. However, its single effect is not necessarily sufficient.

On the other hand, regarding the function of indigestible dextrin, for example, an IgA secretagogue containing indigestible dextrin as an active ingredient (see Patent Document 1) and a drug for renal failure patients containing indigestible dextrin as an active ingredient A blood cresol-lowering agent has been proposed (see Patent Document 2).

JP 2014-152125 A JP 2014-148467 A

An object of the present invention is to provide a blood triglyceride elevation suppressing composition with dramatically improved blood triglyceride elevation suppressing action.

The inventors of the present invention have extensively investigated and researched the effect of indigestible dextrin on suppressing the elevation of blood triglycerides, and found that combining the indigestible dextrin with a specific component greatly enhances the effect of suppressing the elevation of blood triglycerides. The present inventors have found that it is possible to substantially improve the performance, and have completed the present invention. That is, by combining an ingredient with little or no inhibitory effect on blood triglyceride elevation with indigestible dextrin, the effect of indigestible triglyceride elevation is reduced compared to the indigestible dextrin alone. It was found that the inhibitory action can be dramatically improved.

That is, the present invention provides indigestible dextrin, pine bark extract, processed barley grass, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, sodium pantothenate, vitamin E, and a selenium compound. and at least one component selected from the group consisting of the following as an active ingredient.

The blood triglyceride elevation suppressing composition of the present invention may be obtained by adding an active ingredient.

In the composition for suppressing elevation of blood triglycerides of the present invention, the weight ratio of the indigestible dextrin and other active ingredients is preferably in the range of 0.5:1 to 70:1.
In addition, the blood triglyceride elevation suppressing composition of the present invention is preferably a tablet, capsule, powder, granule, or liquid.

The present invention also relates to a method for suppressing an increase in blood neutral fat (excluding medical practice), which comprises ingesting the composition for suppressing an increase in blood neutral fat of the present invention.

According to the blood triglyceride elevation suppressing composition of the present invention, the blood triglyceride elevation suppressing action can be dramatically improved as compared with the case of indigestible dextrin alone.

FIG. 10 is a diagram showing the secreted triglyceride (TG) concentration after absorption into the Caco-2 monolayer when the composition for suppressing elevation of blood triglycerides of the present invention is applied, showing the pine bark extract together with the indigestible dextrin. shows the results when using FIG. 4 is a diagram showing secreted triglyceride (TG) concentration after absorption into Caco-2 monolayer membrane when the composition for suppressing elevation of blood triglyceride of the present invention is applied. , pectin, and tannic acid. It is a diagram showing the secreted triglyceride (TG) concentration after absorption into the Caco-2 monolayer when the composition for suppressing elevation of blood triglycerides of the present invention was applied, and alanine was used together with indigestible dextrin. shows the results for the case. It is a diagram showing the triglyceride (TG) concentration secreted after absorption into the Caco-2 monolayer when the composition for suppressing elevation of blood triglycerides of the present invention was applied, and valine was used together with indigestible dextrin. shows the results for the case. FIG. 4 is a diagram showing secreted triglyceride (TG) concentration after absorption into Caco-2 monolayer membrane when the composition for suppressing elevation of blood triglyceride of the present invention is applied, and vitamin A is used together with indigestible dextrin. The results are shown when It is a diagram showing the secreted triglyceride (TG) concentration after absorption into the Caco-2 monolayer when the composition for suppressing elevation of blood triglycerides of the present invention is applied, showing vitamin B1 and niacin together with indigestible dextrin. , shows the results when using sodium pantothenate. FIG. 4 is a diagram showing secreted triglyceride (TG) concentration after absorption into Caco-2 monolayer membrane when the composition for suppressing elevation of blood triglyceride of the present invention is applied, and vitamin E is used together with indigestible dextrin. The results are shown when FIG. 4 is a diagram showing secreted triglyceride (TG) concentration after absorption into Caco-2 monolayer membrane when the composition for suppressing elevation of blood triglyceride of the present invention is applied. Sodium selenate) is shown.

The blood triglyceride elevation suppressing composition of the present invention comprises indigestible dextrin, pine bark extract, processed barley grass, collagen, pectin, tannin, alanine, valine, vitamin A, vitamin B1, niacin, and pantothenic acid. It is characterized by containing at least one component (hereinafter sometimes referred to as other component) selected from the group consisting of sodium, vitamin E, and selenium compounds as an active ingredient.

[Indigestible dextrin]
The indigestible dextrin, which is the active ingredient of the composition for suppressing elevation of blood triglycerides of the present invention, is an indigestible polysaccharide that is difficult to be hydrolyzed by human digestive enzymes (amylase). After hydrolysis, it is hydrolyzed with amylase, and a component that is difficult to be hydrolyzed can be purified and obtained. This indigestible dextrin is commercially available in the form of powder, fine granules, granules, etc., and these commercial products can be used. Moreover, since the indigestible dextrin is water-soluble, it may be used in the form of an aqueous solution.

[Other ingredients]
(Pine bark extract)
Examples of the pine that is the raw material for the pine bark extract include French maritime pine (Pinus Martima), larch, Japanese black pine, and Japanese red pine. Martima) is preferred. The extract can be obtained by extraction using a suitable solvent, and examples of solvents that can be used include water (hot water, warm water), ethanol, and hydrous ethanol. The extract contains proanthocyanidins as well as oligomeric proanthocyanidins at a high concentration. For example, the extract preferably contains 20% by mass or more of oligomeric proanthocyanidins relative to the dry mass of the extract.

(Processed young barley leaves)
Two-rowed barley, six-rowed barley, and the like can be used as barley as a raw material for the processed barley grass. As the processed product of young barley leaves, a processed product such as a pulverized product, squeezed juice, or extract of young barley leaves can be used. Powders, granules and the like can be mentioned as pulverized products. The squeezed juice or extract may be in liquid form, but may also be used in the form of paste or dry powder. The extract can be obtained by extraction using a suitable solvent, and examples of solvents that can be used include water (hot water, warm water), ethanol, and hydrous ethanol.

(collagen)
The collagen may be animal-derived collagen or synthetic collagen. In addition to collagen proteins, collagen peptides obtained by hydrolyzing collagen proteins, and telopeptide portions obtained by treating collagen molecules with protease. contains atelocollagen with the As the animal-derived collagen, fish-derived collagen is particularly preferable. Although the average molecular weight (weight average molecular weight) of collagen is not particularly limited, it is preferably from 500 to 100,000, more preferably from 1,000 to 50,000.

(pectin)
The pectin may be plant-derived pectin or synthetic pectin. Plant-derived pectins include, for example, extracts from fruits such as apples and citrus, and vegetables. Pectin is classified into HM pectin with a high degree of esterification and LM pectin with a low degree of esterification, and either pectin may be used. Moreover, as pectin, the pectin marketed as a gelling agent, a thickening agent, etc. can be used.

(tannin)
The tannins may be hydrolyzable tannins or condensed tannins, such as those obtained from persimmon fruit, chestnut astringent skin, quintuple, tamarind seed coat, cod powder, gall, and mimosa bark. Extracts may be mentioned. _{Alternatively} , tannic acid ( _C76H52O46 ) can be used _.

The composition for suppressing elevation of blood neutral fat of the present invention is preferably an agent for suppressing elevation of blood neutral fat used for suppressing elevation of blood neutral fat. Such an agent for suppressing elevation of blood neutral fat contains indigestible dextrin and other prescribed ingredients, and can be distinguished from other products as a product in that it is used to suppress elevation of blood neutral fat. For example, the main body, package, instruction manual, or promotional material of the product according to the present invention indicates that it has a function of suppressing the increase of blood triglycerides. Included within the scope of the present invention. For example, pharmaceuticals (including quasi-drugs), so-called health foods such as foods for specified health uses, foods with nutrient function claims, functional foods whose efficacy has been approved by designated organizations, feeds, etc. can be mentioned. For so-called health foods, labeling such as "suppresses increase in triglycerides", "those who are concerned about triglycerides", "suppresses fat absorption", "those with high triglycerides", etc. can be exemplified. These health foods may be ingested separately from meals, but are preferably ingested with meals, for example, preferably between 1 hour before and 1 hour after meals. More preferably, it is ingested from 5 hours to 0.5 hours after meals, and more preferably from 0.5 hours before meals to the start of meals or during meals.

Examples of the form of the blood triglyceride elevation suppressing composition of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, Rounds, pastes, creams, caplets, gels, chewables, sticks and the like can be mentioned. Among these, tablets, capsules, powders, granules and liquids are particularly preferred. Specifically, supplements, packaged beverages filled in PET bottles, cans, bottles, etc., instant powdered beverages and instant granule beverages for dissolving in water (hot water), milk, fruit juice, green juice, etc. can be exemplified. These are preferable in that they are easy to drink with meals and can improve palatability.

The contents of the indigestible dextrin and other ingredients (active ingredients) in the composition for suppressing elevation of blood triglycerides of the present invention may be appropriately contained within the range in which the effects thereof are exhibited.

In general, when the blood triglyceride elevation suppressing composition of the present invention is a drug or supplement (tablet, capsule), the active ingredient is contained in an amount of 0.01 to 100% by mass in terms of dry mass of the whole. It is preferably contained in an amount of 0.1 to 85% by mass, more preferably 0.5 to 70% by mass.

When the blood triglyceride elevation suppressing composition of the present invention is a packaged beverage (liquid formulation), it preferably contains 0.1 to 10% by mass of the total active ingredient in terms of dry mass. It is more preferably contained in an amount of 3 to 6% by mass, more preferably 0.5 to 4% by mass.

In addition, when the blood neutral fat elevation suppressing composition of the present invention is an instant powdered beverage (powder) or an instant granular beverage (granules), the active ingredient is 10 to 100% by mass of the total in terms of dry mass. It is preferably contained, more preferably 50 to 100% by mass, even more preferably 80 to 100% by mass.

In order to exhibit the effects of the present invention particularly effectively, the active ingredient should be contained in an amount of 80% by mass or more in terms of dry mass of the total composition (excluding water) for suppressing elevation of blood triglycerides of the present invention. The content is preferably 90% by mass or more, more preferably 95% by mass or more, and particularly preferably 100% by mass.

The amount of intake of the blood triglyceride elevation suppressing composition of the present invention is not particularly limited, but from the viewpoint of exhibiting the effects of the present invention more remarkably, the daily intake of the active ingredient is 500 mg/day or more. more preferably 1 g/day or more, more preferably 2 g/day or more, and 4 g/day or more is particularly preferred.

The blood triglyceride elevation suppressing composition of the present invention is divided into one container, or divided into a plurality of containers such as 2 to 3, so that the daily intake is the above-mentioned intake, and is used for one day. can accommodate.

In addition, although the composition for suppressing elevation of blood neutral fat of the present invention may be taken separately from a meal, it can particularly effectively suppress a transient postprandial elevation of blood neutral fat. It is preferably taken during meals, for example, preferably between 1 hour before meals and 1 hour after meals, and preferably between 0.5 hours before meals and 0.5 hours after meals. More preferably, it is ingested from 0.5 hours before meals to the start of meals or during meals.

The blending weight ratio of the indigestible dextrin and other ingredients is preferably in the range of 0.5:1 to 70:1, more preferably in the range of 0.75:1 to 60:1 in terms of dry weight. is more preferred, a range of 1:1 to 60:1 is more preferred, and a range of 1:1 to 50:1 is particularly preferred. When the blending ratio of the indigestible dextrin and other ingredients is within the above range, the effects of the present invention can be exhibited more effectively.

The blood triglyceride elevation suppressing composition of the present invention can be produced by a known formulation method by adding ingredients other than orally acceptable active ingredients, if necessary.

In addition, as the blood neutral fat elevation suppressing composition of the present invention, in addition to a blood neutral fat elevation suppressing composition containing an active ingredient, a blood neutral fat obtained by adding an active ingredient to food Examples include fat elevation suppressing compositions (blood triglyceride elevation suppressing foods), for example, foods with an increased active ingredient content of the present invention compared to ordinary foods (including natural foods) , foods to which active ingredients of the present invention are added to foods that do not normally contain the active ingredients of the present invention. In addition, as the composition for suppressing elevation of blood triglycerides of the present invention, a high-fat food having a fat content of 10% by mass or more, preferably 20% by mass or more, from the viewpoint of more effectively exhibiting the effects of the present invention. A high-fat food that suppresses elevation of blood triglycerides obtained by adding an active ingredient to is preferable. When adding the active ingredients, each ingredient may be added separately, may be added at the same time, or may be added together with other ingredients other than the active ingredient.

Foods for suppressing elevation of blood triglycerides of the present invention include, for example, beverages such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juices; frozen desserts such as ice cream, ice sherbet, and shaved ice; Noodles such as , vermicelli, Chinese noodles, instant noodles; sweets such as candies, candies, gums, chocolates, tablets, snacks, biscuits, jellies, jams, creams, baked goods, breads; Processed livestock foods; dairy products such as processed milk, fermented milk, and yogurt; fats and oils such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressings, and processed foods thereof; seasonings such as sauces and soy sauce; Retort pouch foods such as stew, oyakodon, porridge, porridge, Chinese rice bowl, katsudon, tempura rice bowl, beef bowl, hayashi rice, omelet rice, oden, mapo dofu, dumplings, shumai, hamburger steak, meatballs, various sauces, various soups, etc. can be mentioned.

The method of the present invention for suppressing an increase in blood neutral fat is characterized by ingesting the above-described composition for suppressing an increase in blood neutral fat of the present invention, but does not include medical practice. The blood triglyceride elevation suppressing composition of the present invention may be ingested separately from meals. For example, it is preferably taken between 1 hour before and 1 hour after meals, more preferably between 0.5 hours before and 0.5 hours after meals. , more preferably from 0.5 hours before meals to the start of meals or during meals. As the method of the present invention, for example, a method of suppressing the increase of blood neutral fat by providing the composition for suppressing the increase of blood neutral fat of the present invention together with high-fat foods at a restaurant such as a restaurant. can be mentioned.

EXAMPLES The present invention will be described below based on examples.
[Example 1]
Suppression of triglyceride absorption (suppression of blood triglyceride elevation) was evaluated by a human colon cancer-derived cell Caco-2 monolayer absorption and secretion test. Caco-2 cells are known to differentiate into intestinal epithelium-like cells by culturing, and intestinal absorbability can be evaluated by measuring the amount of substances permeated through the Caco-2 monolayer membrane.

1. Sample preparation 0.2 mM lysophosphatidylcholine, 0.1 mM oleic acid, 0.1 mM 2-monooleoylglycerol, and 2 mM sodium taurodeoxycholate were adjusted and sonicated to prepare micelles of 300-500 nm.

The micelles prepared above and the test substance (indigestible dextrin alone, or indigestible dextrin + other components shown in Table 1) were added to DMEM to adjust the desired final concentration.

2. Caco-2 Monolayer Absorption and Secretion Test 100 μL of sample was added to the Caco-2 monolayer insert wells and kept in a 37° C., 5% CO ₂ incubator. After 24 hours, 600 μL of the solution on the basement membrane side was collected, 200 μL of CHCl ₃ :MeOH=2:1 was added, and after vortexing, centrifugation was performed. The lower layer (organic layer) was recovered, 200 μL of CHCl ₃ :MeOH=2:1 was added again, and after vortexing, centrifugation was performed. The lower layer (organic layer) was collected and the organic layer was dried. 20 μL 2-propanol was added and a triglyceride (TG) measurement was performed. A Wako kit (Triglyceride E-Test Wako) was used for TG measurement.

The results are shown in Table 1 and FIGS. 1 to 8. In each graph in the figure, for the control (hard to digest), "-" indicates no addition, and "+" indicates single addition of 200 µg/mL indigestible dextrin. In the case where other ingredients are indicated, "-+" indicates the addition of other ingredients alone, and "++" indicates the addition of 200 μg/mL indigestible dextrin + other ingredients.

Commercially available indigestible dextrin powder was used as the indigestible dextrin.
As for the young barley leaves, dry pulverized powder was used.
For pine bark, a hot water extract (dry powder) of French maritime pine bark was used.
For sweet potato young leaves, dry ground powder was used.

As shown in Table 1 and Figures 1-8, the combination of indigestible dextrin and certain other ingredients of the present invention synergistically reduced the amount of fat passing through the Caco-2 monolayer. Therefore, it can be seen that the blood triglyceride elevation suppressing composition of the present invention can effectively suppress the blood triglyceride elevation.

[Example 2] (Production of tablets)
Each component was mixed in the ratio shown below, and tableted with a tableting machine.

Ingredient Composition (mg)
indigestible dextrin 135
Barley grass powder 150
Excipient 120
Vitamin B1 15
Anhydrous citric acid 15
Alanine 10
Valine 10

By ingesting several tablets per day, for example, it is expected that an effect of suppressing an increase in blood triglycerides can be obtained.

[Example 3] (Production of capsules)
Each component was mixed in the proportions shown below to form granules according to a conventional method, and 250 mg of the granules were filled into capsules to prepare capsules.
Ingredients Weight parts
indigestible dextrin 15
Pine bark extract 1
Collagen 1
Vitamin E 0.1
Excipient 5

By ingesting several capsules per day, for example, it is expected that an effect of suppressing an increase in blood triglycerides can be obtained.

[Example 4] (Production of granules)
Each component was mixed in the proportions shown below to prepare granules according to a conventional method, and 800 mg of the granules were packed in an aluminum stick.
Ingredients Weight parts
indigestible dextrin 15
Young barley leaves 1
Excipient 5
Anhydrous citric acid 0.1
Tannic acid 0.01

By ingesting several bags of the present granules per day, for example, it is expected that an effect of suppressing an increase in blood triglycerides can be obtained.

[Example 5] (manufacture of liquid agent)
A container was filled with 1 part by weight of pine bark extract, 5 parts by weight of green barley powder, 3 parts by weight of 15 parts by weight of indigestible dextrin hydrolyzed collagen, an appropriate amount of vitamin C, and 200 ml of water, and sealed to prepare a solution.

INDUSTRIAL APPLICABILITY The composition for suppressing elevation of blood neutral fat of the present invention is highly industrially useful because it has the effect of suppressing elevation of blood neutral fat.

Claims (2)

A composition for suppressing elevation of triglycerides containing indigestible dextrin and vitamins. 2. The composition according to claim 1, wherein said vitamin is one or more selected from vitamin A, vitamin B1, sodium pantothenate and vitamin E.